NCT05418803View on ClinicalTrials.gov

BE Study of Two Formulations of Rivaroxaban 2.5 mg in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 28, 2020

Primary Completion Date

February 14, 2020

Study Completion Date

February 14, 2020

Conditions
Healthy Volunteer
Interventions
DRUG

YHP1807 Tab. 2.5mg

Rivaroxaban 2.5mg

DRUG

YHR1901 Tab. 2.5mg

Rivaroxaban 2.5mg

Trial Locations (1)

54907

Jeonbuk National University Hospital, Jeonju

All Listed Sponsors
lead

Yuhan Corporation

INDUSTRY

NCT05418803 - BE Study of Two Formulations of Rivaroxaban 2.5 mg in Healthy Subjects | Biotech Hunter | Biotech Hunter